Previous 10 | Next 10 |
2023-11-20 12:59:05 ET Gainers: Mira Pharmaceuticals ( MIRA ) +58% . YPF ADR ( YPF ) +39% . Altamira Therapeutics Ltd ( CYTO ) +39% . ProKidney Corp ( PROK ) +35% . Soluna Holdings ( SLNH ) +32% . Safety Shot ( SHOT ) +...
Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for ...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), m...
Alzamend’s recently completed Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for ...
2023-10-30 08:34:07 ET More on Alzamend Neuro Alzamend Neuro granted extension by Nasdaq panel Seeking Alpha’s Quant Rating on Alzamend Neuro Historical earnings data for Alzamend Neuro Financial information for Alzamend Neuro For further detai...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder...
Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval Alzamend recently completed a Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects showing a benign safety/ tolerability profile while characterizing dosing levels ...
Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for a Section (505)(b)(2) NDA pathw...
2023-09-27 11:00:53 ET More on Alzamend Neuro Alzamend Neuro granted extension by Nasdaq panel Seeking Alpha’s Quant Rating on Alzamend Neuro Historical earnings data for Alzamend Neuro Financial information for Alzamend Neuro For further detai...
2023-09-22 13:42:16 ET More on Alzamend Neuro Seeking Alpha’s Quant Rating on Alzamend Neuro Historical earnings data for Alzamend Neuro Financial information for Alzamend Neuro For further details see: Alzamend Neuro granted extension by Nasdaq panel
News, Short Squeeze, Breakout and More Instantly...
Alzamend Neuro Inc. Company Name:
ALZN Stock Symbol:
NASDAQ Market:
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...
On Thursday, Alzamend Neuro Inc (NASDAQ:ALZN) entered into a Securities Purchase Agreement with an institutional investor for the purchas...